Human Anti-HLA-DR Recombinant Antibody (clone HD8) (CAT#: HPAB-1156WJ)
This product is a human antibody produced from human antibody-producing mouse. This antibody can be used as a preventive or therapeutic agent for diseases caused by an HLA-DR-expressing cell, especially, a therapeutic agent for malignant tumors.
Specific Inquiry
WB
Figure 1 Delineation of the HD8 epitope on human leukocyte antigenDR (HLA-DR).
HD8 recognizes the β-chain of HLA-DR protein. Affinity-purified HLA-DR protein from SKW6.4 cells was subjected twice to sodium dodecyl sulfate-polyacrylamide gel electrophoresis in non-reducing conditions.
Tawara, T., Hasegawa, K., Sugiura, Y., Tahara, T., Ishida, I., & Kataoka, S. (2007). Fully human antibody exhibits pan‐human leukocyte antigen‐DR recognition and high in vitro/vivo efficacy against human leukocyte antigen‐DR‐positive lymphomas. Cancer science, 98(6), 921-928.
FC
Figure 2 Delineation of the HD8 epitope on human leukocyte antigenDR (HLA-DR).
Peptide #31 (61–73) competes with HD8 for binding to the Raji lymphoma cell line.
Tawara, T., Hasegawa, K., Sugiura, Y., Tahara, T., Ishida, I., & Kataoka, S. (2007). Fully human antibody exhibits pan‐human leukocyte antigen‐DR recognition and high in vitro/vivo efficacy against human leukocyte antigen‐DR‐positive lymphomas. Cancer science, 98(6), 921-928.
ADCC
Figure 3 Ability of IgG1- and IgG2-type HD8 to induce antibodydependent cellular cytotoxicity (ADCC).
51Cr-labeled Raji cells were incubated with increasing concentrations of IgG1-type HD8, original (IgG2-type) HD8, the chimeric mouse-human IgG1 rituximab, or the control antibody together with human effector peripheral blood mononuclear cells (ADCC assay). The specific lysis ratios were then calculated.
Tawara, T., Hasegawa, K., Sugiura, Y., Tahara, T., Ishida, I., & Kataoka, S. (2007). Fully human antibody exhibits pan‐human leukocyte antigen‐DR recognition and high in vitro/vivo efficacy against human leukocyte antigen‐DR‐positive lymphomas. Cancer scice, 98(6), 921-928.
CMCD
Figure 4 Ability of IgG1- and IgG2-type HD8 to induce complement-dependent cytotoxicity (CDC).
51Cr-labeled Raji cells were incubated with increasing concentrations of IgG1-type HD8, original (IgG2-type) HD8, the chimeric mouse-human IgG1 rituximab, or the control antibody together with 5% complement sera (CDC assay). The specific lysis ratios were then calculated.
Tawara, T., Hasegawa, K., Sugiura, Y., Tahara, T., Ishida, I., & Kataoka, S. (2007). Fully human antibody exhibits pan‐human leukocyte antigen‐DR recognition and high in vitro/vivo efficacy against human leukocyte antigen‐DR‐positive lymphomas. Cancer scice, 98(6), 921-928.
Inhib
Figure 5 Anti-tumor activity of HD8 in lymphoma–xenograft mouse models.
Scid mice were pretreated with antiasialo GM1 antisera on day -1, inoculated with Raji or MC/CAR lymphoma cells intravenously on day 0, and treated with 5, 50 or 500 µg/kg of HD8, rituximab, and control IgG on day 5.
Tawara, T., Hasegawa, K., Sugiura, Y., Tahara, T., Ishida, I., & Kataoka, S. (2007). Fully human antibody exhibits pan‐human leukocyte antigen‐DR recognition and high in vitro/vivo efficacy against human leukocyte antigen‐DR‐positive lymphomas. Cancer scice, 98(6), 921-928.
Inhib
Figure 6 Anti-tumor activity of HD8 in lymphoma–xenograft mouse models.
NOD/scid mice were pretreated with antiasialo GM1 antisera on day -1, inoculated with Raji or MC/CAR lymphoma cells intravenously on day 0, and treated with 5, 50 or 500 µg/kg of HD8, rituximab, and control IgG on day 5.
Tawara, T., Hasegawa, K., Sugiura, Y., Tahara, T., Ishida, I., & Kataoka, S. (2007). Fully human antibody exhibits pan‐human leukocyte antigen‐DR recognition and high in vitro/vivo efficacy against human leukocyte antigen‐DR‐positive lymphomas. Cancer scice, 98(6), 921-928.
ADCC
Figure 7 A diagram shows the antibody-dependent cellular cytotoxicity (ADCC) of the purified human anti-HLA-DR monoclonal antibody.
Shows the ADCC activities of HD8G1, HD8G2, HD8G2Ser, HD8G4, HD4G1, HD4G2Ser, and HD4G4.
CMCD
Figure 8 A diagram shows the complement-dependent cytotoxicity (CDC) of the purified human anti-HLA-DR monoclonal antibody.
Shows the CDC activities of HD8G1, HD8G2, HD8G2Ser, HD8G4, HD4G1, HD4G2Ser, and HD4G4.
Specifications
- Immunogen
- Human HLA-DR-expressing Cell
- Host Species
- Human
- Type
- Human IgG2
- Specificity
- Human HLA-DR
- Species Reactivity
- Human
- Clone
- HD8
- Applications
- WB, FC, ADCC, CMCD, Inhib
- Related Disease
- Malignant tumors
Product Property
- Purity
- >95% as determined by SDS-PAGE and HPLC analysis
- Concentration
- Please refer to the vial label for the specific concentration.
- Buffer
- PBS
- Preservative
- No preservatives
- Storage
- Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Applications
- Application Notes
- The HLA-DR antibody has been reported in applications of Western Blot, Flow Cytometry, Antibody-dependent Cell-mediated Cytotoxicity, Complement Mediated Cell Depletion, Inhibition.
Inhib: 5, 50 or 500 µg/kg.
Target
- Alternative Names
- HLA-DR; Human Leukocyte Antigen-DR; L243
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Clone HD8"
See other products for "HLA-DR"
Recombinant Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MOB-503 | Recombinant Anti-human HLA-DR Antibody | WB, IHC, FuncS | IgG |
| FN-103CQ | Mouse Anti-HLA-DR Recombinant Antibody (clone L243) | FC, Block | Mouse IgG2a |
| HPAB-1155WJ | Human Anti-HLA-DR Recombinant Antibody (clone HD4) | Inhib, ADCC, CMCD | Human IgG1 |
| HPAB-1206WJ | Mouse Anti-HLA-DR Recombinant Antibody (HPAB-1206WJ) | FuncS, FC | Mouse IgG2b, κ |
| HPAB-2054-FY | Human Anti-HLA-DR Recombinant Antibody (clone I-2) | FC | Human IgG1 |
Fab Fragment Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MOB-503-F(E) | Recombinant Anti-human HLA-DR Antibody Fab Fragment | RIA, IF, FuncS | Fab |
| HPAB-1542-FY-S(P) | Human Anti-HLA-DR Recombinant Antibody (clone M0042); Fab Fragment | WB, ELISA | Human Fab |
| HPAB-1155WJ-F(E) | Human Anti-HLA-DR Recombinant Antibody (clone HD4); Fab Fragment | ELISA | Human Fab |
| HPAB-1156WJ-F(E) | Human Anti-HLA-DR Recombinant Antibody (clone HD8); Fab Fragment | ELISA | Human Fab |
| HPAB-2054-FY-F(E) | Human Anti-HLA-DR Recombinant Antibody (clone I-2); Fab Fragment | FC | Human Fab |
Mouse Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-094CT | Anti-Human HLA-DR Recombinant Antibody ( L243) | FC, Inhib | |
| TAB-094CT-S(P) | Anti-Human HLA-DR Recombinant Antibody scFv Fragment ( L243) | ELISA, WB | |
| TAB-094CT-F(E) | Anti-Human HLA-DR Recombinant Antibody Fab Fragment ( L243) | ELISA, WB |
Humanized Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-095CT | Anti-Human HLA-DR β Recombinant Antibody (1D09C3) | FC, Inhib, WB, IHC | Humanized antibody |
| TAB-095CT-S(P) | Anti-Human HLA-DR β Recombinant Antibody scFv Fragment (1D09C3) | ELISA | Humanized antibody |
| TAB-095CT-F(E) | Anti-Human HLA-DR β Recombinant Antibody Fab Fragment (1D09C3) | ELISA | Humanized antibody |
scFv Fragment Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| HPAB-0210-WJ-S(P) | Human Anti-HLA-DR Recombinant Antibody (clone DR4B117); scFv Fragment | ELISA, WB | Human scFv |
| HPAB-0050-YJ-S(P) | Human Anti-HLA-DR Recombinant Antibody (clone HD8G2Ser); scFv Fragment | ELISA, WB | Human scFv |
| HPAB-1155WJ-S(P) | Human Anti-HLA-DR Recombinant Antibody (clone HD4); scFv Fragment | ELISA | Human scFv |
| HPAB-1156WJ-S(P) | Human Anti-HLA-DR Recombinant Antibody (clone HD8); scFv Fragment | ELISA | Human scFv |
| HPAB-1206WJ-S(P) | Mouse Anti-HLA-DR Recombinant Antibody; scFv Fragment (HPAB-1206WJ-S(P)) | WB, FC | Mouse scFv |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for HPAB-1156WJ. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.